New developments in the management of major depressive disorder and generalized anxiety disorder: Role of quetiapine

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1181-1192

  Baune, Bernhard T ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Adverse effects; General anxiety disorder; Major depressive disorders; Quetiapine; Randomized controlled studies

Indexed keywords

AMFEBUTAMONE; DULOXETINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADJUVANT THERAPY; APPETITE; ARTICLE; BLURRED VISION; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERHIDROSIS; INSOMNIA; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; POLLAKISURIA; QUALITY OF LIFE; RHINOPHARYNGITIS; SEDATION; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 60249088162     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3238     Document Type: Article

References (58)

1. Alexiadis M, Whitehom D, Woodley H, et al. 2002. Prolactin elevation with quetiapine. Am J Psychiatry, 159:1608-9.
2. Ananth J. 1998. Treatment-resistant depression. Psychother Psychosom, 67:61-70.
3. Arango C, Bernardo M. 2005. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol, 20:237-41.
4. Atmaca M, Kuloglu M, Tezcan E, et al. 2002. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res, 33:562-5.
5. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry, 154: 672-6.
6. Baune BT, Caliskan S, Todder D. 2007. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol, 22:1-9.
7. Berk M, Dodd S. 2005. Efficacy of atypical antipsychotics in bipolar disorder. Drugs, 65:257-69.
8. Calabrese JR, Keck PE Jr, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry, 162:1351-60.
9. Chouinard G, Ahokas A, Bandelow B, et al. 2008. Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD): a placebo-controlled study with active-comparator paroxetine. Anxiety Disorders Association of America Congress. Savannah, Georgia, USA.
10. Cohrs S, Rodenbeck A, Guan Z, et al. 2004. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl), 174:421-9.
11. Croissant B, Klein O, Gehrlein L, et al. 2006. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry, 21:570-3.
12. Dando TM, Keating GM. 2005. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs, 65: 2533-51.
13. Dannlowski U, Baune BT, Bockermann I, et al. in press. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol.
14. Datto C, Lam R, Lepola U, et al. 2008. Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD). 161st Annual Meeting of the American Psychiatric Association. Washington DC, USA.
15. DeVane CL, Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet, 40:509-22.
16. Diaz E, Neuse E, Sullivan MC, Pearsall HR. and Woods SW. 2004. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry, 65: 354-60.
17. Doree JP, Des Rosiers J, Lew V, et al. 2007. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin, 23:333-41.
18. El-Khalili N, Banov M, Bortnick B, et al. 2008a. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder (MDD): a randomized, placebo-controlled clinical trial (Study 003). 63rd Annual Society of Biological Psychiatry. Washington DC, USA.
19. El-Khalili N, Joyce M, Atkinson S, et al. 2008b. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. 161st Annual Meeting of the American Psychiatric Association. Washington DC, USA.
20. Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am, 19:179-200.
21. Ferrier IN. 1999. Treatment of major depression: is improvement enough? J Clin Psychiatry, 60(Suppl 6):10-4.
22. Gao K, Muzina D, Gajwani P, et al. 2006. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry, 67:1327-40.
23. Gefvert O, Bergstrom M, Langstrom B, et al. 1998. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl), 135:119-26.
24. Ghaemi SN, Katzow JJ. 1999. The use ofquetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry, 11:137-40.
25. Hanley MJ, Kenna GA. 2008. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm, 65:611-8.
26. Hirschfeld RM, Weisler RH, Raines SR, et al. 2006. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 67:355-62.
27. Iskedjian M, Einarson TR, Mackeigan LD, et al. 2002. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther, 24:302-16.
28. Jensen NH, Rodriguiz RM, Caron MG, et al. 2008. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HTIA agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology, 33:2303-12.
29. Kahn RS, Schulz SC, Palazov VD, et al. 2007. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 68:832-42.
30. Kapur S, Zipursky R, Jones C, et al. 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry, 57:553-9.
31. Katzman MA, Vermani M, Jacobs L, et al. in press. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trial. J Anxiety Disord.
32. Katzman M, Brawman-Mintzer O, Reyes E, et al. 2008. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. 63rd Annual Society of Biological Psychiatry. Washington, DC, USA.
33. Keating GM, Robinson DM. 2007. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs, 67:1077-95.
34. Kennedy SH, Lam R. W. 2003. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord, 5(Suppl 2):36-47.
35. Khan A, Joyce M, Eggens I, et al. 2008. Extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of patients with generalized anxiety disorder (GAD). Anxiety Disorders Association of America Congress. Savannah, Georgia, USA.
36. Khazaal Y, Tapparel S, Chatton A, et al. 2007. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry, 31:727-30.
37. Moller HJ, Johnson S, Mateva T, et al. 2008. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol, 23:95-105.
38. Montgomery S, Cutler A, Lazarus A, et al. 2008. Extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of patients with major depressive disorder (MDD). 16th European Congress of Psychiatry. Nice, France.
39. Nakonezny PA, Byerly MJ, Rush AJ. 2007. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs quetiapine. J Sex Marital Ther, 33:203-16.
40. Nemeroff CB. 2005. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry, 66(Suppl 8): 13-21.
41. Nierenberg AA, Wright EC. 1999. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry, 60(Suppl 22):7-11.
42. Philip NS, Carpenter LL, Tyrka AR, et al. 2008. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract, 14:34-44.
43. Richelson E, Sunder T. 2000. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 68:29-39.
44. Rush A, Trivedi MT. 1995. Treating depression to remission. Psychiatr Ann, 9:704-5.
45. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. 2006. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology (Berl), 187:511-4.
46. Saller CF, Salama AI. 1993. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl), 112:285-92.
47. Sattar SP, Bhatia SC, Petty F. 2004. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci, 29:452-7.
48. Savaskan E, Schnitzler C, Schroder C, et al. 2006. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol, 9:507-16.
49. Shelton RC, Papakostas GI. 2008. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 117:253-9.
50. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl, 212:11-9.
51. Sokolski KN, Denson TF. 2003. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry, 27:863-6.
52. Srisurapanont M, Maneeton B, Maneeton N. 2004. Quetiapine for schizophrenia. Cochrane Database Syst Rev, CD000967.
53. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. 2002. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry, 63:992-7.
54. Thase ME, Macfadden W, Weisler RH, et al. 2006. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol, 26:600-9.
55. Todder D, Caliskan S, Baune BT. 2006. Night locomotor activity and quality of sleep in quetiapine-treated patients with depression. J Clin Psychopharmacol, 26:638-42.
56. Vieta E. 2005. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmachol, 3: [Epub ahead of print].
57. Weisler RH, Calabrese JR, Thase ME, et al. 2008b. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry, 69:769-82.
58. Weisler R, Joyce M, McGill L, et al. 2008a. Extended release quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study. American Psychiatric Association. Washington, DC, USA.